Multiple sclerosis, disease-modifying drugs and risk for adverse perinatal and pregnancy outcomes: Results from a population-based cohort study.
Disease-modifying therapies
epidemiology
multiple sclerosis
pregnancy
Journal
Multiple sclerosis (Houndmills, Basingstoke, England)
ISSN: 1477-0970
Titre abrégé: Mult Scler
Pays: England
ID NLM: 9509185
Informations de publication
Date de publication:
05 2023
05 2023
Historique:
medline:
12
5
2023
pubmed:
19
4
2023
entrez:
19
04
2023
Statut:
ppublish
Résumé
There is a paucity of information on maternal multiple sclerosis (MS) and risk of adverse pregnancy and perinatal outcomes. The aim of this study was to determine the association between MS and risks of adverse pregnancy and perinatal outcomes in women with MS. In women with MS, the influence of exposure to disease-modifying therapy (DMT) was also investigated. Population-based retrospective cohort study on singleton births to mothers with MS and matched MS-free mothers from the general population in Sweden between 2006 and 2020. Women with MS were identified through Swedish health care registries, with MS onset before child's birth. Of 29,568 births included, 3418 births were to 2310 mothers with MS. Compared with MS-free controls, maternal MS was associated with increased risks of elective caesarean sections, instrumental delivery, maternal infection and antepartum haemorrhage/ placental abruption. Compared with offspring of MS-free women, neonates of mothers with MS were at increased risks of medically indicated preterm birth and being born small for gestational age. DMT exposure was not associated with increased risks of malformations. While maternal MS was associated with a small increased risk of few adverse pregnancy and neonatal outcomes, DMT exposure close to pregnancy was not associated with major adverse outcomes.
Sections du résumé
BACKGROUND
There is a paucity of information on maternal multiple sclerosis (MS) and risk of adverse pregnancy and perinatal outcomes.
OBJECTIVE
The aim of this study was to determine the association between MS and risks of adverse pregnancy and perinatal outcomes in women with MS. In women with MS, the influence of exposure to disease-modifying therapy (DMT) was also investigated.
METHODS
Population-based retrospective cohort study on singleton births to mothers with MS and matched MS-free mothers from the general population in Sweden between 2006 and 2020. Women with MS were identified through Swedish health care registries, with MS onset before child's birth.
RESULTS
Of 29,568 births included, 3418 births were to 2310 mothers with MS. Compared with MS-free controls, maternal MS was associated with increased risks of elective caesarean sections, instrumental delivery, maternal infection and antepartum haemorrhage/ placental abruption. Compared with offspring of MS-free women, neonates of mothers with MS were at increased risks of medically indicated preterm birth and being born small for gestational age. DMT exposure was not associated with increased risks of malformations.
CONCLUSIONS
While maternal MS was associated with a small increased risk of few adverse pregnancy and neonatal outcomes, DMT exposure close to pregnancy was not associated with major adverse outcomes.
Identifiants
pubmed: 37073483
doi: 10.1177/13524585231161492
pmc: PMC10176621
doi:
Substances chimiques
Pharmaceutical Preparations
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
731-740Références
Epidemiology. 2019 Mar;30(2):230-233
pubmed: 30721167
JAMA Neurol. 2014 Jul 1;71(7):891-5
pubmed: 24821217
Mult Scler Relat Disord. 2017 Feb;12:4-8
pubmed: 28283105
Neurology. 2018 Mar 6;90(10):e823-e831
pubmed: 29438046
Am J Obstet Gynecol. 2002 Mar;186(3):446-52
pubmed: 11904605
BMJ Open. 2012 Jul 04;2(4):
pubmed: 22763662
Eur J Epidemiol. 2016 Feb;31(2):125-36
pubmed: 26769609
J Perinat Med. 2017 May 24;45(4):455-460
pubmed: 27124670
Am J Epidemiol. 2019 Jan 1;188(1):57-66
pubmed: 30165561
Pharmacoepidemiol Drug Saf. 2007 Jul;16(7):726-35
pubmed: 16897791
Mult Scler. 2010 Aug;16(8):950-5
pubmed: 20542921
Neurology. 2005 Dec 27;65(12):1961-3
pubmed: 16380620
Neurology. 2009 Dec 1;73(22):1831-6
pubmed: 19923552
Obstet Gynecol Int. 2012;2012:148616
pubmed: 22190949
Ther Adv Neurol Disord. 2020 Oct 07;13:1756286420951072
pubmed: 33101459
Acta Neurol Scand. 2021 Dec;144(6):680-686
pubmed: 34357597
Mult Scler. 2021 Mar;27(3):475-478
pubmed: 32538681
Mult Scler. 2009 May;15(5):606-12
pubmed: 19318510
Rev Neurol (Paris). 2021 Mar;177(3):180-194
pubmed: 32736812
Acta Neurol Scand. 2015;132(199):11-9
pubmed: 26046553
Neurol Neuroimmunol Neuroinflamm. 2020 Dec 17;8(1):
pubmed: 33334856
Mult Scler. 2016 May;22(6):810-6
pubmed: 26754804
Mult Scler Relat Disord. 2019 Feb;28:172-176
pubmed: 30611102
Acta Neurol Scand. 2018 Oct;138(4):327-331
pubmed: 29797711
Neurology. 2018 Oct 23;91(17):e1559-e1569
pubmed: 30266889
Ann Neurol. 2011 Jul;70(1):41-50
pubmed: 21710652
J Matern Fetal Neonatal Med. 2018 Feb;31(3):382-387
pubmed: 28139946
Neurol Clin Pract. 2021 Aug;11(4):280-290
pubmed: 34484927
BMC Public Health. 2011 Jun 09;11:450
pubmed: 21658213